# LINKER-MM3 (NCT05730036)

> A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

No report yet. It can be ordered.

- Drugs tested: linvoseltamab
- Indication: relapsed/refractory multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05730036
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Regeneron Pharmaceuticals
- Conditions: Relapsed Refractory Multiple Myeloma (RRMM)
- Interventions: Linvoseltamab; Elotuzumab; Pomalidomide; Dexamethasone
- Enrollment: 410
- Primary outcome: Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) response criteria determined by Independent Review Committee (IRC) in CD38 antibody exposed participants

## Indexed commentary on LINKER-MM3 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 10
- Podcasts: 5
- X threads: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=linker-mm3-nct05730036

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05730036", "email": "<work email>"}; the inbox owner confirms by the emailed link.